Corixa

Immunotherapeutics for treating and preventing infectious diseases and cancer

Corixa was a biopharmaceutical company focusing on innovative oncology and immunology-based products. The company received FDA approval for BEXXAR, an anti-CD20 antibody conjugated to a radioactive I-131 moeity, to treat non-Hodgkin's lymphoma. Corixa also develped a novel adjuvant, MPL, that has been used in multiple investigational and approved vaccines. Corixa completed its IPO on NASDAQ in 1997 and was acquired by GSK in 2005.

Status

IPO in 1997 (NASDAQ: CRXA); acquired by GlaxoSmithKline in 2005

Year of Investment

1996

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Seattle, Washington